{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:52:14Z","timestamp":1779126734470,"version":"3.51.4"},"reference-count":98,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI18\/00766"],"award-info":[{"award-number":["PI18\/00766"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["CB06\/03\/0018"],"award-info":[{"award-number":["CB06\/03\/0018"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"\u201cRio Hortega\u201d program","award":["CM20\/00212"],"award-info":[{"award-number":["CM20\/00212"]}]},{"name":"\u201cRio Hortega\u201d program","award":["CM20\/00125"],"award-info":[{"award-number":["CM20\/00125"]}]},{"name":"\u201cRio Hortega\u201d program","award":["CM21\/00110"],"award-info":[{"award-number":["CM21\/00110"]}]},{"name":"\u201cMiguel Servet Type II\u201d program","award":["CPII\/00014"],"award-info":[{"award-number":["CPII\/00014"]}]},{"name":"\u201cNicolas Monardes\u201d program","award":["C1-0005-2020"],"award-info":[{"award-number":["C1-0005-2020"]}]},{"DOI":"10.13039\/100020230","name":"Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades","doi-asserted-by":"crossref","award":["PREDOC-00826"],"award-info":[{"award-number":["PREDOC-00826"]}],"id":[{"id":"10.13039\/100020230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>The prevalence of type 2 diabetes mellitus (T2DM) is rising in the general population. This increase leads to higher cardiovascular risk, with cardiovascular diseases being the main cause of death in diabetic patients. New therapeutic weapons for diabetes mellitus are now available. Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are novel drugs that are widely used due to their strong benefit in preventing hospitalization for decompensated heart failure and renal protection, limiting the deterioration of the glomerular filtration rate, independently of the presence of diabetes mellitus. These drugs have also shown benefit in the prevention of atherosclerotic cardiovascular events and cardiovascular mortality in diabetic patients with established cardiovascular disease. On the other hand, patients with T2DM usually present a high burden of associated comorbidities. Some of these entities are arterial hypertension, dyslipidemia, hyperuricemia, obesity, non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), vascular aging, respiratory diseases, or osteoporosis and fractures. Healthcare professionals should treat these patients from an integral point of view, and not manage each pathology separately. Therefore, as potential mechanisms of SGLT2 inhibitors in metabolic diseases have not been fully reviewed, we conducted this review to know the current evidence of the use and effect of SGLT2 inhibitors on these metabolic diseases.<\/jats:p>","DOI":"10.31083\/j.rcm2402036","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T09:03:44Z","timestamp":1675328624000},"source":"Crossref","is-referenced-by-count":6,"title":["Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases"],"prefix":"10.31083","volume":"24","author":[{"given":"Jaime","family":"Sanz-C\u00e1novas","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ricci","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Cobos-Palacios","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"L\u00f3pez-Sampalo","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halbert","family":"Hern\u00e1ndez-Negr\u00edn","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"V\u00e1zquez-M\u00e1rquez","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Mancebo-Sevilla","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"\u00c1lvarez-Recio","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"L\u00f3pez-Carmona","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"P\u00e9rez-Velasco","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Miguel","family":"P\u00e9rez-Belmonte","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"G\u00f3mez-Huelgas","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERobn), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Rosa","family":"Bernal-L\u00f3pez","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA-Plataforma Bionand), 29590 M\u00e1laga, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERobn), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"ref1","unstructured":"International Diabetes Federation. IDF diabetes Atlas. 9th edn. International Diabetes Federation: Brussels, Belgium. 2019."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Demir S, Nawroth PP, Herzig S, Ekim \u00dcst\u00fcnel B. Emerging Targets in Type 2 Diabetes and Diabetic Complications. Advanced Science. 2021; 8: e2100275.","DOI":"10.1002\/advs.202100275"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinology and Metabolism Clinics of North America. 2021; 50: 337\u2013355.","DOI":"10.1016\/j.ecl.2021.05.013"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Rubio-Almanza M, C\u00e1mara-G\u00f3mez R, Merino-Torres JF. Obesidad y diabetes mellitus tipo 2: tambi\u00e9n unidas en opciones terap\u00e9uticas. Endocrinolog\u00eda, Diabetes Y Nutrici\u00f3N. 2019; 66: 140\u2013149.","DOI":"10.1016\/j.endinu.2018.08.003"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Aras M, Tchang BG, Pape J. Obesity and Diabetes. Nursing Clinics of North America. 2021; 56: 527\u2013541.","DOI":"10.1016\/j.cnur.2021.07.008"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Correia JC, Waqas A, Huat TS, Gariani K, Jornayvaz FR, Golay A, et al. Effectiveness of Therapeutic Patient Education Interventions in Obesity and Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2022; 14: 3807.","DOI":"10.3390\/nu14183807"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019; 92: 6\u201310.","DOI":"10.1016\/j.metabol.2018.09.005"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Nitschke E, Gottesman K, Hamlett P, Mattar L, Robinson J, Tovar A, et al. Impact of Nutrition and Physical Activity Interventions Provided by Nutrition and Exercise Practitioners for the Adult General Population: A Systematic Review and Meta-Analysis. Nutrients. 2022; 14: 1729.","DOI":"10.3390\/nu14091729"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Forouhi NG, Misra A, Mohan V, Taylor R, Yancy W. Dietary and nutritional approaches for prevention and management of type 2 diabetes. British Medical Journa. 2018; 361: k2234.","DOI":"10.1136\/bmj.k2234"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Brown A, McArdle P, Taplin J, Unwin D, Unwin J, Deakin T, et al. Dietary strategies for remission of type 2 diabetes: a narrative review. Journal of Human Nutrition and Dietetics. 2022; 35: 165\u2013178.","DOI":"10.1111\/jhn.12938"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Pel\u00e1ez S, Fito M, Castaner O. Mediterranean Diet Effects on Type 2 Diabetes Prevention, Disease Progression, and Related Mechanisms. A Review. Nutrients. 2020; 12: 2236.","DOI":"10.3390\/nu12082236"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Alonso-Dom\u00ednguez R, Garc\u00eda-Ortiz L, Patino-Alonso MC, S\u00e1nchez-Aguadero N, G\u00f3mez-Marcos MA, Recio-Rodr\u00edguez JI. Effectiveness of A Multifactorial Intervention in Increasing Adherence to the Mediterranean Diet among Patients with Diabetes Mellitus Type 2: A Controlled and Randomized Study (EMID Study). Nutrients. 2019; 11: 162.","DOI":"10.3390\/nu11010162"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021; 44: S111\u2013S124.","DOI":"10.2337\/dc21-S009"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Van Steenbergen A, Balteau M, Ginion A, Fert\u00e9 L, Battault S, Ravenstein CDMD, et al. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Scientific Reports. 2017; 7: 41166.","DOI":"10.1038\/srep41166"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Ordelheide AM, B\u00f6hm A, Kempe-Teufel D, Wagner R, Machicao F, Heni M, et al. Common variation in the sodium\/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations. PLoS ONE. 2017; 12: e0177148.","DOI":"10.1371\/journal.pone.0177148"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Klen J, Dol\u017ean V. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. International Journal of Molecular Sciences. 2021; 22: 9800.","DOI":"10.3390\/ijms22189800"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Current Opinion in Endocrinology & Diabetes and Obesity. 2017; 24: 73\u201379.","DOI":"10.1097\/MED.0000000000000311"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Santos-Ferreira D, Gon\u00e7alves-Teixeira P, Fontes-Carvalho R. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with one Stone? Cardiology. 2020; 145: 311\u2013320.","DOI":"10.1159\/000504694"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Failure Reviews. 2021; 26: 623\u2013642.","DOI":"10.1007\/s10741-020-10038-w"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy. 2014; 8: 1335\u20131380.","DOI":"10.2147\/DDDT.S50773"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to Fatty Substrate Utilization in Response to Sodium\u2013Glucose Cotransporter 2 Inhibition in Subjects without Diabetes and Patients with Type 2 Diabetes. Diabetes. 2016; 65: 1190\u20131195.","DOI":"10.2337\/db15-1356"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in diabetes-2021. Diabetes Care. 2021; 44: S125\u2013S150.","DOI":"10.2337\/dc21-S010"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017; 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019; 380: 347\u2013357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine. 2020; 383: 1425\u20131435.","DOI":"10.1056\/NEJMoa2004967"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019; 380: 2295\u20132306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine. 2019; 381: 1995\u20132008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine. 2020; 383: 1413\u20131424.","DOI":"10.1056\/NEJMoa2022190"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. European Journal of Heart Failure. 2019; 21: 1279\u20131287.","DOI":"10.1002\/ejhf.1596"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020; 383: 1436\u20131446.","DOI":"10.1056\/NEJMoa2024816"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Katsiki N, Tousoulis D. Diabetes mellitus and comorbidities: a bad romance. Hellenic Journal of Cardiology. 2020; 61: 23\u201325.","DOI":"10.1016\/j.hjc.2020.02.009"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Zhao Y, Qie R, Han M, Huang S, Wu X, Zhang Y, et al. Association of BMI with cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus: a systematic review and dose\u2013response meta-analysis of cohort studies. Nutrition, Metabolism and Cardiovascular Diseases. 2021; 31: 1976\u20131984.","DOI":"10.1016\/j.numecd.2021.03.003"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Luo J, Hodge A, Hendryx M, Byles JE. BMI trajectory and subsequent risk of type 2 diabetes among middle-aged women. Nutrition, Metabolism and Cardiovascular Diseases. 2021; 31: 1063\u20131070.","DOI":"10.1016\/j.numecd.2020.12.019"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Larsson SC, Burgess S. Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of Mendelian randomization studies. BMC Medicine. 2021; 19: 320.","DOI":"10.1186\/s12916-021-02188-x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Kan Y, Liu L, Li X, Pang J, Bi Y, Zhang L, et al. Association between distinct body mass index trajectories according to the group\u2010based trajectory modeling and the risk of incident diabetes: a systematic review. Obesity Reviews. 2022; 23: e13508.","DOI":"10.1111\/obr.13508"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Cho YK, Kim Y, Jung CH. Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: a Systematic Review and a Meta-Analysis. Journal of Obesity & Metabolic Syndrome. 2021; 30: 336\u2013344.","DOI":"10.7570\/jomes21061"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Bolinder J, Ljunggren \u00d6, Johansson L, Wilding J, Langkilde AM, Sj\u00f6str\u00f6m CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism. 2014; 16: 159\u2013169.","DOI":"10.1111\/dom.12189"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Wong J, Chan KY, Lo K. Sodium\u2010glucose co\u2010transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: a meta\u2010analysis. Obesity Reviews. 2021; 22: e13336.","DOI":"10.1111\/obr.13336"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Zheng H, Liu M, Li S, Shi Q, Zhang S, Zhou Y, et al. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology. 2021; 12: 706914.","DOI":"10.3389\/fendo.2021.706914"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Shi Y, Si Y, Fu R, Zhang M, Jiang K, Dai W, et al. Efficacy and safety of SGLT-2i in overweight\/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials. Endokrynologia Polska. 2022; 73: 71\u201380.","DOI":"10.5603\/EP.a2021.0102"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Garc\u00eda A, Simental-Mend\u00eda M, Mill\u00e1n-Alan\u00eds JM, Simental-Mend\u00eda LE. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials. Pharmacological Research. 2020; 160: 105068.","DOI":"10.1016\/j.phrs.2020.105068"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Chen M, Wang H, Cui W, Xu H, Zheng Q. Effect of SGLT inhibitors on weight and lipid metabolism at 24\u200aweeks of treatment in patients with diabetes mellitus: A systematic review and network meta-analysis. Medicine. 2021; 100: e24593.","DOI":"10.1097\/MD.0000000000024593"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opinion on Drug Metabolism & Toxicology. 2018; 14: 1113\u20131121.","DOI":"10.1080\/17425255.2018.1541348"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Gupta R, Maitz T, Egeler D, Mehta A, Nyaeme M, Hajra A, et al. SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure. Trends in Cardiovascular Medicine. 2022. (online ahead of print)","DOI":"10.1016\/j.tcm.2022.05.005"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vascular Health and Risk Management. 2016; 12: 393\u2013405.","DOI":"10.2147\/VHRM.S111991"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Kravtsova O, Bohovyk R, Levchenko V, Palygin O, Klemens CA, Rieg T, et al. SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats. American Journal of Physiology-Renal Physiology. 2022; 322: F692\u2013F707.","DOI":"10.1152\/ajprenal.00053.2022"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. Journal of the American Society of Hypertension. 2014; 8: 262\u2013275.e9.","DOI":"10.1016\/j.jash.2014.01.007"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Majewski C, Bakris GL. Blood Pressure Reduction: an Added Benefit of Sodium\u2013Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes. Diabetes Care. 2015; 38: 429\u2013430.","DOI":"10.2337\/dc14-1596"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Abdul-Ghani MA, DeFronzo RA. Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. Journal of Internal Medicine. 2014; 276: 352\u2013363.","DOI":"10.1111\/joim.12244"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovascular Diabetology. 2022; 21: 45.","DOI":"10.1186\/s12933-022-01480-1"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Zanchi A, Pruijm M, Muller ME, Ghajarzadeh-Wurzner A, Maillard M, Dufour N, et al. Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects. Frontiers in Cardiovascular Medicine. 2022; 9: 854230.","DOI":"10.3389\/fcvm.2022.854230"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Tran KC, Hiremath S. SGLT2 Inhibitors in Resistant Hypertension: a Sweet Solution. American Journal of Hypertension. 2020; 33: 1071\u20131074.","DOI":"10.1093\/ajh\/hpaa100"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Katsiki N, Dimitriadis GD, Mikhailidis DP. Serum Uric Acid and Diabetes: from Pathophysiology to Cardiovascular Disease. Current Pharmaceutical Design. 2021; 27: 1941\u20131951.","DOI":"10.2174\/1381612827666210104124320"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Bletsa E, Paschou SA, Tsigkou V, Stampouloglou PK, Vasileiou V, Kassi GN, et al. The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review. Hormones (Athens). 2022. (online ahead of print)","DOI":"10.1007\/s42000-022-00403-9"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Bailey CJ. Uric acid and the cardio\u2010renal effects of SGLT2 inhibitors. Diabetes, Obesity and Metabolism. 2019; 21: 1291\u20131298.","DOI":"10.1111\/dom.13670"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Hu X, Yang Y, Hu X, Jia X, Liu H, Wei M, et al. Effects of sodium\u2010glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: a systematic review and network meta\u2010analysis. Diabetes, Obesity and Metabolism. 2022; 24: 228\u2013238.","DOI":"10.1111\/dom.14570"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Hussain M, Elahi A, Hussain A, Iqbal J, Akhtar L, Majid A. Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes. Journal of Diabetes Research. 2021; 2021: 9973862.","DOI":"10.1155\/2021\/9973862"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Yip ASY, Leong S, Teo YH, Teo YN, Syn NLX, See RM, et al. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Therapeutic Advances in Chronic Disease. 2022; 13: 20406223221083509.","DOI":"10.1177\/20406223221083509"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Banerjee M, Pal R, Mukhopadhyay S. Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis. Acta Diabetologica. 2022; 59: 783\u2013791.","DOI":"10.1007\/s00592-022-01866-3"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Medicine. 2020; 17: e1003100.","DOI":"10.1371\/journal.pmed.1003100"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, et al. Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Digestive and Liver Disease. 2021; 53: 44\u201351.","DOI":"10.1016\/j.dld.2020.08.021"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology. 2021; 12: 635556.","DOI":"10.3389\/fendo.2021.635556"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, et al. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: a Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2017; 40: 1364\u20131372.","DOI":"10.2337\/dc17-0518"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Bando Y, Ogawa A, Ishikura K, Kanehara H, Hisada A, Notumata K, et al. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. Diabetology International. 2017; 8: 218\u2013227.","DOI":"10.1007\/s13340-016-0302-y"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase\u20104 in patients with type 2 diabetes and non\u2010alcoholic fatty liver disease. International Journal of Clinical Practice. 2019; 73: e13335.","DOI":"10.1111\/ijcp.13335"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Chrysavgis L, Papatheodoridi A, Chatzigeorgiou A, Cholongitas E. The impact of sodium glucose co\u2010transporter 2 inhibitors on non\u2010alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2021; 36: 893\u2013909.","DOI":"10.1111\/jgh.15202"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Dwinata M, Putera D, Hasan I, Raharjo M. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. Clinical and Experimental Hepatology. 2020; 6: 339\u2013346.","DOI":"10.5114\/ceh.2020.102173"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends in Cardiovascular Medicine. 2020; 30: 399\u2013404.","DOI":"10.1016\/j.tcm.2019.08.010"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World Journal of Diabetes. 2021; 12: 932\u2013938.","DOI":"10.4239\/wjd.v12.i7.932"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Cai M, Shao X, Xing F, Zhang Y, Gao X, Zeng Q, et al. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open\u2010label, noninferiority trial. Diabetes, Obesity and Metabolism. 2022; 24: 312\u2013320.","DOI":"10.1111\/dom.14583"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clinical Endocrinology. 2019; 90: 805\u2013813.","DOI":"10.1111\/cen.13968"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, et al. Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double\u2010blind, phase 2 trial. Diabetes, Obesity and Metabolism. 2021; 23: 2595\u20132599.","DOI":"10.1111\/dom.14495"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. IJC Heart & Vasculature. 2021; 33: 100725.","DOI":"10.1016\/j.ijcha.2021.100725"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Adam CA, Anghel R, Marcu DTM, Mitu O, Roca M, Mitu F. Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review). Life. 2022; 12: 803.","DOI":"10.3390\/life12060803"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Hidalgo Santiago JC, Maraver Delgado J, Cay\u00f3n Blanco M, L\u00f3pez Saez JB, G\u00f3mez-Fern\u00e1ndez P. Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus. Medicina Cl\u00edNica. 2020; 154: 171\u2013174.","DOI":"10.1016\/j.medcle.2019.05.014"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovascular Diabetology. 2017; 16: 138.","DOI":"10.1186\/s12933-017-0621-8"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Solini A, Seghieri M, Giannini L, Biancalana E, Parolini F, Rossi C, et al. The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature. The Journal of Clinical Endocrinology & Metabolism. 2019; 104: 4253\u20134263.","DOI":"10.1210\/jc.2019-00706"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Lunder M, Jani\u0107 M, Japelj M, Jureti\u010d A, Jane\u017e A, \u0160abovi\u010d M. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovascular Diabetology. 2018; 17: 153.","DOI":"10.1186\/s12933-018-0797-6"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Devineni D, Polidori D, Curtin CR, Murphy J, Wang S, Stieltjes H, et al. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Int. Journal of Clinical Pharmacology and Therapeutics. 2015; 53: 438\u2013446.","DOI":"10.5414\/CP202324"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Papadopoulou E, Loutradis C, Tzatzagou G, Kotsa K, Zografou I, Minopoulou I, et al. Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Journal of Hypertension. 2021; 39: 749\u2013758.","DOI":"10.1097\/HJH.0000000000002690"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Patoulias D, Papadopoulos C, Kassimis G, Fragakis N, Vassilikos V, Karagiannis A, et al. Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials. Vascular Medicine. 2022; 27: 433\u2013439.","DOI":"10.1177\/1358863X221101653"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Liu L, Ni Y, Zhan J, Liu Y. The Role of SGLT2 Inhibitors in Vascular Aging. Aging and Disease. 2021; 12: 1323\u20131336.","DOI":"10.14336\/AD.2020.1229"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ. Analysis of Fractures in Patients with Type 2 Diabetes Treated with Empagliflozin in Pooled Data from Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. Diabetes Care. 2018; 41: 1809\u20131816.","DOI":"10.2337\/dc17-1525"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney International. 2014; 85: 962\u2013971.","DOI":"10.1038\/ki.2013.356"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Ljunggren \u00d6, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sj\u00f6str\u00f6m CD, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism. 2012; 14: 990\u2013999.","DOI":"10.1111\/j.1463-1326.2012.01630.x"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, et al. Effects of Canagliflozin on Fracture Risk in Patients with Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism. 2016; 101: 157\u2013166.","DOI":"10.1210\/jc.2015-3167"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, et al. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients with Type 2 Diabetes Treated with Canagliflozin. The Journal of Clinical Endocrinology & Metabolism. 2016; 101: 44\u201351.","DOI":"10.1210\/jc.2015-1860"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Metformin in Subjects with Type 2 Diabetes. Diabetes Care. 2012; 35: 1232\u20131238.","DOI":"10.2337\/dc11-1926"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Ostinelli G, Laforest S, Denham SG, Gauthier M, Drolet-Labelle V, Scott E, et al. Increased Adipose Tissue Indices of Androgen Catabolism and Aromatization in Women with Metabolic Dysfunction. The Journal of Clinical Endocrinology & Metabolism. 2022; 107: e3330\u2013e3342.","DOI":"10.1210\/clinem\/dgac261"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Greco EA, Lenzi A, Migliaccio S. The obesity of bone. Therapeutic Advances in Endocrinology and Metabolism. 2015; 6: 273\u2013286.","DOI":"10.1177\/2042018815611004"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"King S, Klineberg I, Brennan-Speranza TC. Adipose Tissue Dysfunction: Impact on Bone and Osseointegration. Calcified Tissue International. 2022; 110: 32\u201340.","DOI":"10.1007\/s00223-021-00899-0"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Blevins TC, Farooki A. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate Medicine. 2017; 129: 159\u2013168.","DOI":"10.1080\/00325481.2017.1256747"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Arnott C, Fletcher RA, Neal B. Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk. Heart Failure Clinics. 2022; 18: 645\u2013654.","DOI":"10.1016\/j.hfc.2022.03.008"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis. Frontiers in Endocrinology. 2021; 12: 735824.","DOI":"10.3389\/fendo.2021.735824"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"McGill JB, Subramanian S. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. The American Journal of Cardiology. 2019; 124: S45\u2013S52.","DOI":"10.1016\/j.amjcard.2019.10.029"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Qiu M, Ding LL, Zhan ZL, Liu SY. Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. Endocrine. 2021; 73: 31\u201336.","DOI":"10.1007\/s12020-021-02644-x"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Yin DG, Qiu M, Duan XY. Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials. Frontiers in Pharmacology. 2021; 12: 724405.","DOI":"10.3389\/fphar.2021.724405"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/24\/2\/10.31083\/j.rcm2402036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:28:36Z","timestamp":1732732116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/24\/2\/10.31083\/j.rcm2402036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"alternative-id":["S1530-6550(22)00785-2"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2402036","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"article-number":"36"}}